The human papillomavirus (HPV) is a sexually transmitted infection with certain strains being a known etiology of cervical cancer in women. There are over 100 different types of HPV, which can range from low to high risk. The HPV strains that should be covered in a new treatment include HPV types 16,18, 31, and 45. These are all extremely high-risk strains of HPV and are responsible for approximately 80% of cervical cancer cases. Other strains such as HPV types 33 and 58, among others, are also associated with cervical cancer but not to the extent as the previously mentioned high-risk strains. As a result of HPV being a sexually transmitted infection, treatment in the form of a vaccine should be administered prior to the start of sexual activity to prevent the infection from occurring in the first place. Although it would be highly beneficial to include all strains of HPV in the new treatment if there aren’t sufficient funds the high-risk strains should certainly be covered. If there are more available funds, more research is required to determine the severity of the other strains of HPV (HPV 33, 35, 39, 51, 52, 56, 58, and 59) in regard to cervical cancer. If a certain strain is deemed high-risk, it should be added to the treatment plan.